Trial Profile
Using the monoclonal antibody Nimotuzumab in treating patients with squamous cell carcinoma of head and neck in advanced stages.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 14 Nov 2018 Results assessing efficiency of healthcare presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 11 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by Cuban Clinical Trial Registry.
- 06 Sep 2011 New trial record